Search results
GSK is a leading biopharma company with a presence in Singapore since 1959. It produces vaccines, medicines and specialty care products, and employs over 1,500 people in Singapore.
- Search Jobs
GSK plc. Registered in England and Wales No. 3888792....
- Manufacturing and Supply
Manufacturing and Supply - Singapore | GSK
- Media Contacts
Media Contacts - Singapore | GSK
- Quarterly Results
GSK plc. Registered in England and Wales No. 3888792....
- London (Rns)
London (Rns) - Singapore | GSK
- Analyst Consensus
GSK neither endorses, concurs nor accepts responsibility...
- New York (Sec)
New York (Sec) - Singapore | GSK
- Debt Investors
GSK has access to short-term finance under a $10 billion US...
- Search Jobs
GSK - Global Network. The wide range of Electronics components at the Good price and Best service. IPO Division. IPO DIVISION is dedicated to provide customers with efficient component outsourcing, through an extensive network of Manufacturers and Suppliers. Read More. GSK 15th Years Anniversary. More VDO. News Update. 16-09-2021.
Jul 13, 2023 · GSK has invested over $850 million in its Tuas site, which will produce hepatitis B vaccine using a novel technology. The minister praised Singapore's partnership with GSK and its biopharmaceutical industry.
May 21, 2021 · Sales Turnover. 01-06-2021. I am also thankful to our devoted employees for their unwavering support. Their efficiency and readiness at addressing to the needs of our customers enable us to grow steadily. Read More.
THE expansion of British drugmaker GSK’s facility at Tuas has earned it the title of Singapore’s largest vaccine production site based on a cumulative investment of some S$850 million, said Minister for Trade and Industry Gan Kim Yong.
GSK will build a new plant at Tuas to produce drug substances for its Hepatitis B vaccines, which protect against a potentially life-threatening liver infection. The facility will create 100 jobs, use advanced technology and achieve carbon net zero by 2030.
GSK invests S$44m in a high potency manufacturing and testing facility in Jurong, Singapore, to produce a key ingredient for antibody drug conjugates (ADCs). The facility is the first in Singapore to handle highly potent cytotoxic components for breakthrough immunotherapy cancer treatments.
